FENC · Fennec Pharmaceuticals Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on FENC. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About FENC · Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Live Quote
BUY (score +7) · 12-1 mom 18.0% · RSI 69.8 · above_both · 0.0% from high
Targets blend Wall Street consensus (6 analysts: low $13.00 / mean $15.67 / high $18.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Stage produced output that could not be parsed as a valid JSON object. ~6h cooldown before retry.
{"symbol":"FENC","company":"Fennec Pharmaceuticals Inc.","investigation_summary":"Fennec Pharmaceuticals is a commercial-stage specialty pharma with one product, PEDMARK (sodium thiosulfate injection), which prevents cisplatin-induced hearing loss in pediatric cancer patients. The investigation trigger was three Form 4 filings within 14 days — however, all three were director option grants at-the-